New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy

被引：0
|
作者：
Lemaitre, Josephine [1 ,2 ]
Watson, Sarah [3 ,4 ]
机构：
[1] Ctr Oscar Lambret, Dept Med Oncol, 3 Rue Frederic Combemalle, F-59000 Lille, France
[2] Univ Lille, Fac Med Henri Warembourg, Lille, France
[3] Inst Curie, Dept Med Oncol, 26 Rue Ulm, F-75248 Paris 05, France
[4] Univ PSL, Inst Curie, Ctr Rech, Inserm,U830,Canc Heterogene Instabil & Plasc, 26 Rue Ulm, F-75248 Paris 05, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 03期
关键词：
Advanced GIST; Tyrosine kinase inhibitor; KIT; PDGFRA;
D O I：
10.1016/j.bulcan.2022.01.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：250 / 252
页数：4
相关论文
共 50 条
  • [1] Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy
    Fung, Simon
    Shirley, Matt
    [J]. DRUGS, 2022, 82 (15) : 1541 - 1548
  • [2] Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy
    Simon Fung
    Matt Shirley
    [J]. Drugs, 2022, 82 : 1541 - 1548
  • [3] Ripretinib in the treatment of patients with advanced gastrointestinal stromal tumors (GIST)
    Babula, Emilia
    Sikora, Aleksandra
    Sobczuk, Pawel
    Rutkowski, Piotr
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (01): : 40 - 51
  • [4] Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
    Li, Jian
    Cai, Shirong
    Zhou, Yongjian
    Zhang, Jun
    Zhou, Ye
    Cao, Hui
    Wu, Xin
    Deng, Yanhong
    Huang, Zhao
    Dong, Juan
    Shen, Lin
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3425 - 3432
  • [5] Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
    Liao, Weiting
    Xu, Huiqiong
    Hutton, David
    Wu, Qiuji
    Zhou, Kexun
    Luo, Hui
    Lei, Wanting
    Feng, Mingyang
    Yang, Yang
    Wen, Feng
    Li, Qiu
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval
    Goggin, Caitriona
    Stansfeld, Anna
    Mahalingam, Preethika
    Thway, Khin
    Smith, Myles J.
    Huang, Paul
    Jones, Robin L.
    Napolitano, Andrea
    [J]. FUTURE ONCOLOGY, 2022, 18 (26) : 2967 - 2978
  • [7] Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors
    Sargsyan, Amalya
    Kucharczyk, Monika A.
    Jones, Robin L.
    Constantinidou, Anastasia
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 17 (02) : 119 - 127
  • [8] New surgical approaches to localized and advanced gastrointestinal stromal tumors (GIST)
    Bonvalot, Sylvie
    Honore, Charles
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2012, 196 (4-5): : 855 - 860
  • [9] Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)
    Casali, Paolo G.
    Fumagalli, Elena
    Gronchi, Alessandro
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (03) : 277 - 284
  • [10] Gastrointestinal stromal tumors (GIST).: Surgical therapy
    Wente, M. N.
    Buechler, M. W.
    Weitz, J.
    [J]. CHIRURG, 2008, 79 (07): : 638 - 643
12345